Publication:
Esomeprazole in acute and maintenance treatment of reflux oesophagitis: A multicentre prospective study

dc.contributor.authorAtuğ, Özlen
dc.contributor.authorGiral, Adnan
dc.contributor.authorKalaycı, Cem
dc.contributor.authorDolar, Enver
dc.contributor.authorIsıtan, Fahri
dc.contributor.authorOğuz, Dilek
dc.contributor.authorÖvünç, Oya
dc.contributor.authorÖzgür, Orhan
dc.contributor.buuauthorDOLAR, MAHMUT ENVER
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Anabilim Dalı.
dc.contributor.researcheridAAG-9177-2021
dc.date.accessioned2024-11-07T07:33:21Z
dc.date.available2024-11-07T07:33:21Z
dc.date.issued2008-06-01
dc.description.abstractIntroduction: The aim of this study was to assess the efficacy and safety of esomeprazole 40 mg once daily (q.d.) in healing reflux oesophagitis at 4 and 8 weeks, and the efficacy of esomeprazole 20 mg q.d. for 12 weeks in the maintenance of remission.Methods: A total of 235 patients with endoscopically proven reflux oesophagitis were enrolled in this study, which consisted of two phases (healing and maintenance therapy). Patients who showed complete endoscopic and symptomatic healing at the end of 4 or 8 weeks were switched to maintenance treatment with esomeprazole 20 mg q.d. for 12 weeks. The primary efficacy endpoint was healing of reflux oesophagitis at week 8. Secondary assessments included the proportion of patients with symptomatic relapse in the maintenance phase.Results: At the end of week 8, 88% (95% life-table confidence intervals [CI]: 84%, 92%) of patients were healed endoscopically and 90.6% of the patients were asymptomatic. Patient age, gender and Helicobacter pylori status had no effect on the efficacy of treatment. During the 12-week maintenance treatment phase, symptomatic relapse ratios were 0.5%, 2.2%, and 0%, for the first, second, and third 4-week periods, respectively. The proportions of patients satisfied with treatment were 95% and 99.4% at the end of acute and maintenance treatment, respectively. The most common adverse effects were headache, upper respiratory tract infection and abdominal pain.Conclsions: Esomeprazole is effective in the healing of reflux oesophagitis, the resolution of heartburn, and in maintaining symptomatic remission. The effectiveness of esomeprazole in patients with gastroesophageal reflux disease is not affected by the presence of H. pylori.
dc.identifier.doi10.1007/s12325-008-0071-5
dc.identifier.endpage566
dc.identifier.issn0741-238X
dc.identifier.issue6
dc.identifier.startpage552
dc.identifier.urihttps://doi.org/10.1007/s12325-008-0071-5
dc.identifier.urihttps://link.springer.com/article/10.1007/s12325-008-0071-5
dc.identifier.urihttps://hdl.handle.net/11452/47536
dc.identifier.volume25
dc.identifier.wos000257390500002
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherSpringer
dc.relation.journalAdvances in Therapy
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectHealed erosive esophagitis
dc.subjectHelicobacter-pylori infection
dc.subjectIntragastric acid control
dc.subjectProton pump inhibitors
dc.subjectPantoprazole 40 mg
dc.subjectLansoprazole 30 mg
dc.subjectDouble-blind
dc.subjectDisease
dc.subjectOmeprazole
dc.subjectSymptoms
dc.subjectEsomeprazole
dc.subjectHeartburn
dc.subjectMaintenance treatment
dc.subjectReflux oesophagitis
dc.subjectResearch & experimental medicine
dc.subjectPharmacology & pharmacy
dc.titleEsomeprazole in acute and maintenance treatment of reflux oesophagitis: A multicentre prospective study
dc.typeArticle
dspace.entity.typePublication
relation.isAuthorOfPublication9f100906-5262-4b98-9828-2958eac56d15
relation.isAuthorOfPublication.latestForDiscovery9f100906-5262-4b98-9828-2958eac56d15

Files

Collections